← Leaderboards
Shaomeng Wang
University Of Michigan At Ann Arbor
$36,139,079
Attributed
$37,864,696
Total exposure
24
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,633,542 · 25
By mechanism
R01$30,506,354 · 14
U19$7,694,940 · 3
P50$4,836,331 · 5
R21$595,917 · 3
Top collaborators
- Longchuan Bai5 shared
- Yali Dou4 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Zaneta Nikolovska-Coleska$5,411,857
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoDesignSmall MoleculeProteinsBaseTumorLeadCell GrowthIn VitroDrug KineticsToxic EffectAffinityMalignant NeoplasmsInhibitor/AntagonistApoptosisXenograft ModelSpecificityCancer CellTumor TissueDoseBinding (Molecular Function)Clinical TrialsPlayNovel Therapeutics
Grant awards (98)
Orally active CBP/p300 degraders$672,792
R01 · FY2025 · CA · contact PI
Small-molecule degraders of STAT5$646,849
R01 · FY2025 · CA · contact PI
Orally active CBP/p300 degraders$688,392
R01 · FY2024 · CA · contact PI
Small-molecule degraders of STAT5$614,944
R01 · FY2024 · CA · contact PI
Small-molecule STAT3 degraders$548,550
R01 · FY2024 · CA · contact PI
Small-molecule degraders of STAT5$646,994
R01 · FY2023 · CA · contact PI
Small-molecule STAT3 degraders$579,830
R01 · FY2023 · CA · contact PI
Project 3: Exploring Ablation of the Androgen Receptor as a Therapeutic Approach for Castration-Resistant Prostate Cancer$227,349
P50 · FY2023 · CA · contact PI
Targeting the menin-MLL1 complex for new therapeutics$634,124
R01 · FY2022 · CA · contact PI
Small-molecule STAT3 degraders$592,518
R01 · FY2022 · CA · contact PI
Project 3: Exploring Ablation of the Androgen Receptor as a Therapeutic Approach for Castration-Resistant Prostate Cancer$184,258
P50 · FY2022 · CA · contact PI
Small-molecule MDM2 degraders$647,004
R01 · FY2021 · CA · contact PI
Targeting the menin-MLL1 complex for new therapeutics$646,774
R01 · FY2021 · CA · contact PI
Small-molecule STAT3 degraders$620,148
R01 · FY2021 · CA · contact PI
Small-molecule degraders of BET proteins$592,054
R01 · FY2021 · CA · contact PI
Project 3: Exploring Ablation of the Androgen Receptor as a Therapeutic Approach for Castration-Resistant Prostate Cancer$219,324
P50 · FY2021 · CA · contact PI
Targeting the menin-MLL1 complex for new therapeutics$647,740
R01 · FY2020 · CA · contact PI
Small-molecule MDM2 degraders$643,104
R01 · FY2020 · CA · contact PI
Small-molecule STAT3 degraders$643,055
R01 · FY2020 · CA · contact PI
Small-molecule degraders of BET proteins$606,297
R01 · FY2020 · CA · contact PI
Project 3: Exploring Ablation of the Androgen Receptor as a Therapeutic Approach for Castration-Resistant Prostate Cancer$266,760
P50 · FY2020 · CA · contact PI
Targeting the menin-MLL1 complex for new therapeutics$626,786
R01 · FY2019 · CA · contact PI
Small-molecule MDM2 degraders$611,605
R01 · FY2019 · CA · contact PI
Small-molecule degraders of BET proteins$601,424
R01 · FY2019 · CA · contact PI
Project 3: Exploring Ablation of the Androgen Receptor as a Therapeutic Approach for Castration-Resistant Prostate Cancer$261,146
P50 · FY2019 · CA · contact PI
Targeting the menin-MLL1 complex for new therapeutics$646,858
R01 · FY2018 · CA · contact PI
Small-molecule degraders of BET proteins$631,956
R01 · FY2018 · CA · contact PI
Small-molecule MDM2 degraders$624,777
R01 · FY2018 · CA · contact PI
Development of a dual small-molecule BCl-XL/BCL-2 inhibitor for non-small cell lu$321,625
R01 · FY2018 · CA · contact PI
Development of Novel BET Bromodomain Inhibitors for the Treatment of Advanced$273,524
P50 · FY2018 · CA · contact PI
Small-molecule degraders of BET proteins$635,345
R01 · FY2017 · CA · contact PI
Small-molecule MDM2 degraders$615,748
R01 · FY2017 · CA · contact PI
Development of a dual small-molecule BCl-XL/BCL-2 inhibitor for non-small cell lu$321,625
R01 · FY2017 · CA · contact PI
Development of Novel BET Bromodomain Inhibitors for the Treatment of Advanced$260,745
P50 · FY2017 · CA · contact PI
Targeting the MLL-WDR5 protein-protein interaction$451,476
R01 · FY2016 · CA · contact PI
Development of a dual small-molecule BCl-XL/BCL-2 inhibitor for non-small cell lu$321,625
R01 · FY2016 · CA · contact PI
Development of Novel BET Bromodomain Inhibitors for the Treatment of Advanced$257,180
P50 · FY2016 · CA · contact PI
Targeting the MLL-WDR5 protein-protein interaction$468,214
R01 · FY2015 · CA · contact PI
Development of a dual small-molecule BCl-XL/BCL-2 inhibitor for non-small cell lu$321,625
R01 · FY2015 · CA · contact PI
Development of Novel BET Bromodomain Inhibitors for the Treatment of Advanced$260,532
P50 · FY2015 · CA · contact PI
Potent and Highly Selective D3 Ligands for the Treatment of Cocaine Abuse$662,443
R01 · FY2014 · DA · contact PI
Targeting the MLL-WDR5 protein-protein interaction$454,167
R01 · FY2014 · CA · contact PI
Development of a dual small-molecule BCl-XL/BCL-2 inhibitor for non-small cell lu$322,663
R01 · FY2014 · CA · contact PI
Design of Orally Bioavailable IAP Antagonists for Cancer Treatment$260,704
R01 · FY2014 · CA · contact PI
Development of Novel BET Bromodomain Inhibitors for the Treatment of Advanced$258,621
P50 · FY2014 · CA · contact PI
Potent and Highly Selective D3 Ligands for the Treatment of Cocaine Abuse$635,945
R01 · FY2013 · DA · contact PI
Targeting the MLL-WDR5 protein-protein interaction$468,214
R01 · FY2013 · CA · contact PI
Design of Bivalent SMAC Mimetics$290,250
R01 · FY2013 · CA · contact PI
Design of Orally Bioavailable IAP Antagonists for Cancer Treatment$251,844
R01 · FY2013 · CA · contact PI
Potent and Highly Selective D3 Ligands for the Treatment of Cocaine Abuse$15,600
R01 · FY2013 · DA · contact PI
Potent and Highly Selective D3 Ligands for the Treatment of Cocaine Abuse$676,318
R01 · FY2012 · DA · contact PI
Design of Bivalent SMAC Mimetics$308,776
R01 · FY2012 · CA · contact PI
Preclinical Evaluation and Clinical Development of Potent Small-Molecule$278,965
P50 · FY2012 · CA · contact PI
Design of Orally Bioavailable IAP Antagonists for Cancer Treatment$267,920
R01 · FY2012 · CA · contact PI
Therapeutic Potential and Mechanism of Action of Potent Small Molecule Inhibitors$204,633
P50 · FY2012 · CA · contact PI
Design of Bivalent SMAC Mimetics$308,776
R01 · FY2011 · CA · contact PI
Design of Orally Bioavailable IAP Antagonists for Cancer Treatment$267,920
R01 · FY2011 · CA · contact PI
Preclinical Evaluation and Clinical Development of Potent Small-Molecule$265,240
P50 · FY2011 · CA · contact PI
Therapeutic Potential and Mechanism of Action of Potent Small Molecule Inhibitors$195,415
P50 · FY2011 · CA · contact PI
Design, synthesis and characterization of dopamine receptor 3 ligands$605,960
R01 · FY2010 · DA · contact PI
Non-Peptide Small-Molecule Inhibitors of the MDM2-p53 interaction$446,566
R01 · FY2010 · CA · contact PI
Design of Bivalent SMAC Mimetics$318,326
R01 · FY2010 · CA · contact PI
Preclinical Evaluation and Clinical Development of Potent Small-Molecule$279,934
P50 · FY2010 · CA · contact PI
Design of Orally Bioavailable IAP Antagonists for Cancer Treatment$276,207
R01 · FY2010 · CA · contact PI
Therapeutic Potential and Mechanism of Action of Potent Small Molecule Inhibitors$223,544
P50 · FY2010 · CA · contact PI
Discovery of small-molecule inhibitors of the beta-catenin/BCL-9 interaction$154,500
R21 · FY2010 · NS · contact PI
Novel Small-Molecule Inhibitors of Bcl-2/Bcl-xL Protein*$1,108,052
U19 · FY2009 · CA · contact PI
Design, synthesis and characterization of dopamine receptor 3 ligands$595,776
R01 · FY2009 · DA · contact PI
Non-Peptide Small-Molecule Inhibitors of the MDM2-p53 interaction$437,813
R01 · FY2009 · CA · contact PI
Comput. Struct.-Based Design, Chem. Synth., Biochem Charac. and Molec. Mechanism$416,541
U19 · FY2009 · CA · contact PI
Design of Bivalent SMAC Mimetics$318,326
R01 · FY2009 · CA · contact PI
Preclinical Evaluation and Clinical Development of Potent Small-Molecule$279,175
P50 · FY2009 · CA · contact PI
Therapeutic Potential and Mechanism of Action of Potent Small Molecule Inhibitors$225,991
P50 · FY2009 · CA · contact PI
Novel Small-Molecule Inhibitors of Bcl-2/Bcl-xL Protein*$1,181,076
U19 · FY2008 · CA · contact PI
Design, synthesis and characterization of dopamine receptor 3 ligands$576,111
R01 · FY2008 · DA · contact PI
Comput. Struct.-Based Design, Chem. Synth., Biochem Charac. and Molec. Mechanism$445,863
U19 · FY2008 · CA · contact PI
Non-Peptide Small-Molecule Inhibitors of the MDM2-p53 interaction$425,060
R01 · FY2008 · CA · contact PI
Preclinical Evaluation and Clinical Development of Potent Small-Molecule$278,234
P50 · FY2008 · CA · contact PI
Therapeutic Potential and Mechanism of Action of Potent Small Molecule Inhibitors$135,761
P50 · FY2008 · CA · contact PI
Novel Small-Molecule Inhibitors of Bcl-2/Bcl-xL Protein*$1,123,992
U19 · FY2007 · CA · contact PI
Design, synthesis and characterization of dopamine receptor 3 ligands$570,748
R01 · FY2007 · DA · contact PI
Comput. Struct.-Based Design, Chem. Synth., Biochem Charac. and Molec. Mechanism$426,058
U19 · FY2007 · CA · contact PI
Non-Peptide Small-Molecule Inhibitors of the MDM2-p53 interaction$420,850
R01 · FY2007 · CA · contact PI
Design of SMAC Peptidomimetics and Nonpeptidic Mimetics$267,657
R01 · FY2007 · CA · contact PI
Novel Small-Molecule Inhibitors of Bcl-2/Bcl-xL Protein*$1,155,782
U19 · FY2006 · CA · contact PI
Design, synthesis and characterization of dopamine receptor 3 ligands$583,671
R01 · FY2006 · DA · contact PI
Non-Peptide Small-Molecule Inhibitors of the MDM2-p53 interaction$434,268
R01 · FY2006 · CA · contact PI
Comput. Struct.-Based Design, Chem. Synth., Biochem Charac. and Molec. Mechanism$286,178
U19 · FY2006 · CA · contact PI
Design of SMAC Peptidomimetics and Nonpeptidic Mimetics$275,651
R01 · FY2006 · CA · contact PI
Novel Small-Molecule Inhibitors of Bcl-2/Bcl-xL Protein*$1,199,944
U19 · FY2005 · CA
Comput. Struct.-Based Design, Chem. Synth., Biochem Charac. and Molec. Mechanism$286,178
U19 · FY2005 · CA
Design of SMAC Peptidomimetics and Nonpeptidic Mimetics$282,285
R01 · FY2005 · CA
Discovery of Small Molecule Inhibitors of XIAP$160,102
R21 · FY2005 · CA
Administrative Core$65,276
U19 · FY2005 · CA
Design of SMAC Peptidomimetics and Nonpeptidic Mimetics$282,285
R01 · FY2004 · CA
Discovery of Small Molecule Inhibitors of XIAP$172,027
R21 · FY2004 · CA
COCAINE ANTAGONISTS THROUGH 3D PHARMACOPHORE SEARCHING$325,396
R01 · FY2000 · DA
REVERSIBLE FOLDING OF PROTEIN SECONDARY STRUCTURES$109,288
R21 · FY2000 · GM